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Abstract
Background: Adequate endometrial growth is principal for implantation and preg-
nancy. Thin endometrium is associated with lower pregnancy rate in assisted
reproductive technology. Some frozen-thawed embryo transfer cycles are cancelled
due to inadequate endometrial growth.
Objective: To assess the effectiveness of autologous platelet-rich plasma (PRP)
intrauterine infusion for the treatment of thin endometrium.
Materials and Methods: A total of 72 patients who had a history of cancelled frozen-
thawed embryo transfer cycle due to the thin endometrium (< 7mm) were assessed for
the eligibility to enter the study between 2016 and 2017. Twelve patients were excluded
for different reasons, and 60 included patients were randomly assigned to PRP or
sham-catheter groups in a double-blind manner. Hormone replacement therapy was
administered for endometrial preparation in all participants. PRP intrauterine infusion
or shamcatheter was performed on day 11-12 due to the thin endometrium and it was
repeated after 48 hr if necessary.
Results: Endometrial thickness increased at 48 hr after the first intervention in both
groups. All participants needed second intervention due to an inadequate endometrial
expansion. After second intervention, endometrial thickness was 7.21 ± 0.18 and 5.76
± 0.97 mm in the PRP group and sham-catheter group, respectively. There was a
significant difference between the two groups. (p < 0.001). Embryo transfer was done
for all patients in PRP group and just in six cases in the sham-catheter group. Chemical
pregnancy was reported in twelve cases in the PRP group and two cases in the sham-
catheter group.
Conclusion: According to this trial, PRP was effective in endometrial expansion in
patients with refractory thin endometrium.
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1. Introduction
Implantation and pregnancy are influenced by
two main factors, embryo and endometrium. A
healthy embryo and receptive endometrium are
necessary for implantation. Several treatments
are used for endometrial preparation in frozen-
thawed embryo transfer (FET) cycles (1). Endome-
trial pattern and thickness are evaluated by
ultrasound examination. There is no agreement
about the most recipient endometrium, however,
most clinicians prefer endometrial thickness more
than 7 mm for embryo transfer (2-5). Some FET
cycles are canceled due to inadequate endome-
trial growth despite several treatments. Different
protocols such as extended estrogen treatment,
Pentoxifylline, low-dose Aspirin, Tamoxifen, vaginal
Sildenafil, intrauterine perfusion with granulocyte-
colony stimulating factor, and platelet-rich plasma
(PRP) have been performed for the management
of thin endometrium, but there is little consensus
on the most effective one (6-14). PRP intrauterine
infusion is a new approach for the treatment of
refractory thin endometrium, which can stimulate
proliferation and angiogenesis with a large num-
ber of growth factors and cytokines (7-11).PRP is
achieved easily from an autologous blood sample
that eliminates the risk of immunological reactions
and transmission infections with low cost.
The aim of this double-blind randomized sham-
controlled trial was to evaluate the effectiveness of
PRP intrauterine infusion for the treatment of thin
endometrium.
2. Materials and Methods
2.1. Study population
A total of 72 woman who had a history of
cancelled FET cycle due to inadequate endome-
trial growth (≤ 7 mm) despite standard treatments
were assessed for the eligibility to enter the study
between 2016 and 2017. The inclusion criteria were
age ≤ 38 yr and body mass index ≤ 30 kg/m2.
The exclusion criteria were uterine abnormalities,
hormonal disorders, and hematological disorders.
All participants were subjected to the laboratory
evaluation of hormonal and hematological dis-
orders. The hysteroscopic examination was per-
formed before the cycle if it was not previously
done. Twelve women were excluded for different
reasons; sixty were included in the study (Figure 1).
2.2. Study design
This was a single-center, double-blind random-
ized sham-controlled trial (with balanced random-
ization), which was conducted in the IVF Cen-
ter, Taleghani Educational Hospital, Tehran, Iran.
Women were randomly selected to one of the
two different groups according to the method of
treatment: PRP or sham_catheter. Patients, out-
come assessor, and statistician were blinded as
to randomization. Randomization was carried out
using computer-generated simple random tables
in a 1:1 ratio. According to our pilot study the
sample size was calculated after the considera-
tion of type 1 statistical error < 5%; and type 2
statistical error < 20% based on the expected
difference of endometrial thickness between the
two groups. Hormone replacement therapy was
administered for endometrial preparation in all
patients: estradiol valerate (Aburaihan Co., Tehran,
Iran) 6 mg/d was started on the 2nd or 3rd day of
the menstrual cycle and that was increased to 8
mg/d on day 9-10 due to inadequate endometrial
growth (≤ 7 mm). Intrauterine infusion of PRP
or sham_catheter was performed on day 11-12
in intervention or control group due to the thin
endometrium (thickness less than 7 mm), and it
was repeated after 48 hr if required. PRP infu-
sion or sham_catheter was performed under an
ultrasound guidance. During this cycle, whenever
endometrial thickness increased more than 7 mm,
suppository progesterone (Cyclogest; Actavis, the
UK limited, England) 400 mg twice a day was
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started, and ET was carried out on cleavage
stage (on embryonic day 3). Estradiol valerate and
progesterone supplementation were continued for
next 2 weeks after ET and until 12 weeks of
gestation in pregnancy. Transvaginal ultrasound
was carried out by an expert gynecologist with a
fellowship in infertility by onemachine. Endometrial
thickness was measured at the thickest part in the
longitudinal axis of the uterus. PRP was prepared
from autologous blood using a two-step centrifuge
process; as the same protocol as reported in our
pilot study (8). Then, 0.5 ml of PRP was infused into
the uterine cavity with the IUI catheter (Takwin, Iran)
under ultrasound guidance. The dosage and timing
of PRP infusion were determined according to the
pilot studies that were published in reproductive
medicine.
2.3. Outcome assessment
Transvaginal ultrasound examination was done
48 hr after PRP infusion or sham_catheter to
evaluate the endometrial thickness.
Enrollment 
Follow-Up 
Allocated to PRP intrauterine infusion (n = 30) Allocated to sham catheter (n = 30) Allocation 
Assessed for eligibility (n = 72) 
Excluded (n = 12) 
ØNot meeting inclusion criteria (n = 9) 
ØDeclined to participate (n = 3) 
Lost to follow-up (n = 0) 
Randomized (n = 60) 
Analysed (n = 30) Analysis 
Lost to follow-up (n = 0) 
Analysed (n = 30) 
Figure 1. Consort flow diagram.
2.4. Ethical consideration
All patients signed an informed written consent.
The study was approved by the ethical committee
of Shahid Beheshti University of medical sciences,
Tehran, Iran (IR.SBMU.MSP.REC.1394.92).
2.5. Statistical analysis
Results were given as mean ± SD. Statistical
analysis was performed using the SPSS 21.0 soft-
ware package (Statistical Package for the social
sciences, SPSS Inc, Chicago, IL, USA). According to
the distribution of data, t-test and chi-square test
were performed. A p< 0.05was considered signifi-
cant. The primary outcomewas endometrial expan-
sion and secondary outcomes were the chemical
and clinical pregnancy that was determined by a
positive serum βHCG and the presence of fetal
heart beat in transvaginal ultrasound, 2 wk and 5
wk after ET, respectively.
3. Results
3.1. Baseline characteristics
Sixty consenting participants were enrolled in
this study who fulfilled the entry criteria and
abled to complete the study and their data were
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analyzed. Table I shows a summary of the baseline
characteristics of both groups. In term of age, BMI,
and etiology of infertility there were no significant
differences between the groups.
3.2. Outcomes
Table II summarized the endometrial thickness
before and after PRP or sham-catheter intervention.
All participants needed PRP or sham-catheter inter-
vention in the treatment cycles due to inadequate
endometrium growth on day 11-12. As the time
of first intervention, the endometrial thickness
was 4.92 ± 0.67 and 5.06 ± 0.82 mm in the
PRP group and sham-catheter group, respectively.
There was no significant difference between the
two groups (p = 0.613). After the first interven-
tion, endometrial thickness was increased in both
group; 5.99 ± 0.7 and 5.45 ± 0.82 mm in the
PRP group and sham-catheter group, respectively.
There was no significant difference between the
two groups (p = 0.63). All participants needed
second intervention 48 hr after the first one due
to the inadequate endometrial thickness. After
second intervention, endometrial thickness was
7.21 ± 0.18 and 5.76 ± 0.97 mm in the PRP group
and sham-catheter group, respectively. There was
a significant difference between the two groups (p
< 0.001). FET cycle was cancelled in 24 patients
in the sham-catheter group due to the persistent
thin endometrium (endometrial thickness less than
7 mm) 48 hr after second intervention. Embryo
transfer was done for all patients in the PRP
group and just in six cases in the sham-catheter
group. Chemical pregnancy was reported in twelve
cases in the PRP group and two cases in the
sham-catheter group (p = 0.031). Clinical pregnancy
was reported in ten cases in the PRP group
and one case in the sham-catheter group (p =
0.048).
Table I. Baseline characteristics
PRP (n = 30) Sham (n = 30) p-value
Age (yr)* 33.93 ± 2.76 32.33 ± 4.79 0.274
BMI (kg)* 24.3 ± 2.24 25.46 ± 2.68 0.262
Etiology of Infertility**
Male Factor 6 (20) 8 (26.6)
DOR 4 (13.3) 2 (6.6)
Tubal Factor 2 (6.6) 2 (6.6)
Anovulation 6 (20) 4 (13.3)
Mixed 12 (40) 14 (46.6)
0.499
Note: *Data presented as mean ± SD; **data presented as n (%)
No staticalsignificancewas observed between the two groups:
BMI: Body mass index DOR: Diminished ovarian reserve
Table II. Outcomes including endometrial thickness and pregnancy rate
PRP (n = 30) Sham (n = 30) p-value
Endometrial thickness (mm)*
before intervention 4.92 ± 0.671 5.06 ± 0.821 0.613
after 1𝑠𝑡 intervention 5.993 ± 0.701 5.453 ± 0.823 0.63
after 2𝑛𝑑 intervention 7.213 ± 0.188 5.767 ± 0.973 < 0.001$
Chemical pregnancy** 12 (40) 2 (6.7) 0.031$
Clinical pregnancy** 10 (33.3) 1 (3.3) 0.048$
Note: *data presented as mean ± SD; **Data presented as n (%); $: Statically significant; SD: Standard deviation;
PRP: Platelet-rich plasma
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4. Discussion
Adequate endometrial growth is principal
for embryo implantation and pregnancy.
According to the literature, the incidence of
the thin endometrium is about 2.5% in in-vitro
fertilization (IVF) cycles which can lead to cycle
cancellation. Also, an endometrial thickness <
7 mm is associated with lower pregnancy rate
in IVF cycles. Besides the important role of
endometrial thickness for implantation, there is
some evidence about its effects on neonatal
birth weight in assisted reproductive technology
(15-17). Intrauterine infusion of PRP to increase
of endometrial thickness was first proposed by
Change and colleagues in 2015 (7). Successful
endometrial growth was reported in all of
five patients with a history of refractory thin
endometrium. Recent reports from our center
have recommended that intrauterine infusion
of PRP may be effective in the improvement of
endometrial growth, expansion and implantation.
In our pilot trial, 10 patients who had a history
of refractory thin endometrium were recruited
in the study and PRP intrauterine infusion was
administered. Endometrial thickness increased
during 48 hours after first PRP and reached > 7
mm after second PRP. Embryo transfer was carried
out for all patients. Five chemical pregnancies
and four live births were reported (7, 8, 18).
Another pilot study revealed the role of PRP in
the improvement of endometrial thickness and
vascularity in women with suboptimal endometrial
thickness and reduced the incidence of cycle
cancellation (9). Two recent studies suggested
PRP intrauterine infusion for two novel approaches
in assisted reproductive technology. These
papers revealed the effective role of PRP in
regeneration in Asherman’s syndrome and the
positive effects of PRP in the improvement of
pregnancy outcome in repeated implantation
failure (11, 18). PRP is an autologous fraction
of the blood that contains a large amount of
platelet, growth factors and cytokines such as
vascular endothelial growth factor, platelet-
derived growth factor, epidermal growth factor,
fibroblast growth factor, insulin-like growth factor
I, II, transforming growth factor, interleukin 8,
hepatocyte growth factor, and connective
tissue growth factor. Recently, the stimulating,
proliferating, and tissue regenerative effects
of PRP have been used in several medical
conditions in orthopedics, ophthalmology, dental
surgery, and wound healing. According to our
pilot trials, there isn’t any report of maternal,
fetal, and neonatal adverse effects (8, 18-23).
The result of this trial revealed the efficacy
of PRP intrauterine infusion on endometrial
expansion and proliferation in women with
idiopathic thin endometrium. As we know, this
is the first double-blind randomized sham-
controlled trial that evaluated the efficacy of
PRP in endometrial growth. We performed two-
dimensional transvaginal ultrasound examination
for measure endometrial thickness. According to
the role of endometrial vascularity on implantation
and pregnancy and the angiogenetic effects of
PRP, it is suggested to design further studies
and apply color Doppler and three-dimensional
ultrasound examination for the detection of
endometrial and sub-endometrial vasculature
pattern and cavity volume before and after PRP
infusion (24).
5. Conclusion
According to this trial, PRP was effective in
endometrial expansion in patients with refractory
thin endometrium.
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